Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HuCART19-IL18 |
Synonyms | |
Therapy Description |
HuCART19-IL18 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and to secrete IL18, which may increase anti-tumor immune response and induce cytotoxicity against CD19-expressing tumor cells (Hematol. Oncol. 2023; 41: 35-37, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HuCART19-IL18 | Autologous Anti-CD19 CAR IL-18-expressing T Cells | CD19 Immune Cell Therapy 62 | HuCART19-IL18 are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19 and to secrete IL18, which may increase anti-tumor immune response and induce cytotoxicity against CD19-expressing tumor cells (Hematol. Oncol. 2023; 41: 35-37, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05989204 | Phase I | HuCART19-IL18 | TmCD19-IL18 in CD19+ Cancers | Recruiting | USA | 0 |
NCT04684563 | Phase I | HuCART19-IL18 | huCART19-IL18 in NHL/CLL Patients | Recruiting | USA | 0 |